1-20 of 47
Weili Zhao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Clinical Efficacy and Safety of Glofitamab in Chinese Relapsed or Refractory Large B-Cell Lymphoma

Yingyu Dong, Weili Zhao, Li Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6522.
https://doi.org/10.1182/blood-2024-204848
Published: 2024
Journal Articles

A China Survey on the Insights of Patients Living with Follicular Lymphoma: The Real-World Patient Journey Analysis

Yang He, Huilai Zhang, Bing Xu, Zengjun Li, Zheng Song, Qiuhui Jiang, Hui Wang, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 7622.
https://doi.org/10.1182/blood-2024-206977
Published: 2024
Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 6553.
https://doi.org/10.1182/blood-2024-203842
Published: 2024
Journal Articles

Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Shu Cheng, Li Wang, Pengpeng Xu, Muchen Zhang, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 4502.3.
https://doi.org/10.1182/blood-2024-204749
Published: 2024
Journal Articles

Over-Expression of GATA3 in Large B-Cell Lymphoma Predicts Better Prognosis

Fan Zhang, Jiaying Liu, Yuting Dai, Di Fu, Yige Shen, Li Wang, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 6272.
https://doi.org/10.1182/blood-2024-204855
Published: 2024
Journal Articles

Transient Activation of PIEZO1 Mechanosensitive Channel Facilitates Ex Vivo expansion of Hematopoietic Stem Cells

Qiwei Wang, Weili Zhao, He Huang, Pengxu Qian
Journal: Blood
Blood (2024) 144 (Supplement 1): 2649.
https://doi.org/10.1182/blood-2024-193734
Published: 2024
Journal Articles

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Tianyuan Xu, Nan Wang, Rui Sun, Ruichi Li, Di Fu, Yan Zhao, Pengpeng Xu, Shu Cheng, Li Wang, Wei Tang, Zhong Zheng, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 6200.
https://doi.org/10.1182/blood-2024-204775
Published: 2024
Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Wenbin Qian, Ying Lu, Yuhua Li, Dongmei Ji, Xiaojian Zhu, Heng Mei, Ping Li, Changju Qu, Lei Zhang, Keshu Zhou, Hongmei Jing, Ting Niu, Chunyan Ji, Lanfang Li, Hua Yang, Fei Li, Wei Wang, Kailin Xu, Jinghua Zhao, Depei Wu, Yu Hu, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 5115.
https://doi.org/10.1182/blood-2024-207186
Published: 2024
Journal Articles

SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery

Hui Wang, Zhaoru Zhang, Yingli Han, Weili Zhao, Penglei Jiang, Bing Liu, Jia Yu, Fang Wang, Pengxu Qian
Journal: Blood
Blood (2024) 144 (Supplement 1): 438.
https://doi.org/10.1182/blood-2024-199496
Published: 2024
Journal Articles

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Lin Shen, Jing Bao, Lihong Shou, Ying Lu, Qi Zhu, Li Wang, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 4399.
https://doi.org/10.1182/blood-2024-204547
Published: 2024
Journal Articles

Polatuzumab Vedotin, Zanubrutinib, Rituximab and Lenalidomide (Pola-ZR2) Regimen in the Treatment of Unfit or Frail Patients with Diffuse Large B-Cell Lymphoma

Ziyang Shi, Qing Shi, Weili Zhao, Li Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4492.
https://doi.org/10.1182/blood-2024-204808
Published: 2024
Journal Articles

Mechanism and Updated Results of Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

Ying Fang, Weili Zhao, Wang Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4482.
https://doi.org/10.1182/blood-2024-202789
Published: 2024
Journal Articles

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Yige Shen, Yiwen Cao, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 3091.
https://doi.org/10.1182/blood-2023-182603
Published: 2023
Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Yuqin Song, JUN MA, Yan Xie, Huilai Zhang, Zhigang Peng, Yuerong Shuang, Fei Li, Yufu Li, Haiyan Yang, Xiuhua Sun, Liqun Zou, Yunhong Huang, Weili Zhao, Wenrong Huang, Hui Zhou, Mingying Liu, Weiwei Wang, Jing Xu, Yajie Wang, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4458.
https://doi.org/10.1182/blood-2023-181385
Published: 2023
Journal Articles

Selinexor in Combination with Salvage Regimen for Refractory Peripheral T-Cell Lymphoma (PTCL) Patients

Li Wang, Mingci CAI, Yaohui Huang, Pengpeng Xu, Shu Chen, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6211.
https://doi.org/10.1182/blood-2023-183040
Published: 2023
Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Jie Zha, Qinwei Chen, Wei Zhang, Hongmei Jing, Jingjing Ye, Haifeng Yu, Shuhua Yi, Caixia Li, Zhong Zheng, Wei Xu, Zhifeng Li, Lingyan Ping, Xiaohua He, Liling Zhang, Ying Xie, Feili Chen, Xiuhua Sun, Liping Su, Huilai Zhang, Zhijuan Lin, Haiyan Yang, Weili Zhao, Lugui Qiu, Zhiming Li, Yuqin Song, Bing Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3048.
https://doi.org/10.1182/blood-2023-182812
Published: 2023
Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results

Xinxin Cao, Jie Jin, Fu Cheng Cheng, Shuhua Yi, Weili Zhao, Zimin Sun, Wei Yang, Dengju Li, Guohui CUI, Jianda Hu, Ting Liu, Yongping Song, Bing Xu, Zunmin Zhu, Wei Xu, Mingzhi Zhang, Sichen Li, Weige Wang, Renbin Zhao, Daobin Zhou
Journal: Blood
Blood (2023) 142 (Supplement 1): 3039.
https://doi.org/10.1182/blood-2023-181500
Published: 2023
Journal Articles

Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

Li Wang, Ying Fang, Muchen Zhang, Jie Xiong, Pengpeng Xu, Shu Chen, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 1745.
https://doi.org/10.1182/blood-2023-182674
Published: 2023
Journal Articles

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Yige Shen, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 4488.
https://doi.org/10.1182/blood-2023-188042
Published: 2023
Journal Articles

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Kaiyang Ding, Yao Liu, Zengjun Li, Neha Mehta-Shah, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yuerong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin Zhai, Liqun Zou, Yaming Xi, Youngil Koh, Fei Li, Miles Prince, Hui Zhou, Lie Lin, Hui Liu, Zhenfan Yang, Won Seog Kim, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 305.
https://doi.org/10.1182/blood-2023-172962
Published: 2023